Magle Group announced the establishment of a collaboration and exclusive worldwide distribution agreement with the global medical device company Sirtex Medial pertaining to its chemoembolization product EmboCept®? S DSM 50 um. The main purpose is to accelerate internationalization, drive growth in new geographic areas, and support the expansion of Magle Group's product portfolio in this important medical field.